Research Article

Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation

  1. Ioannis U. Isaias MD1,2,3,
  2. Riccardo Benti MD2,
  3. Stefano Goldwurm MD1,
  4. Michela Zini MD1,3,
  5. Roberto Cilia MD1,3,
  6. Paolo Gerundini MD2,
  7. Alessio Di Fonzo MD4,5,
  8. Vincenzo Bonifati MD4,6,
  9. Gianni Pezzoli MD1,
  10. Angelo Antonini MD1,*

Article first published online: 2 MAY 2006

DOI: 10.1002/mds.20909

Issue

Movement Disorders

Movement Disorders

Volume 21, Issue 8, pages 1144–1147, August 2006

Additional Information

How to Cite

Isaias, I. U., Benti, R., Goldwurm, S., Zini, M., Cilia, R., Gerundini, P., Di Fonzo, A., Bonifati, V., Pezzoli, G. and Antonini, A. (2006), Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. Mov. Disord., 21: 1144–1147. doi: 10.1002/mds.20909

Author Information

  1. 1

    Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy

  2. 2

    IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy

  3. 3

    Department of Neurology, University of Milano-Bicocca, Milan, Italy

  4. 4

    Erasmus MC Rotterdam, Rotterdam, The Netherlands

  5. 5

    Centro Dino Ferrari, Department of Neurological Sciences, University of Milan, Milan, Italy

  6. 6

    Department of Neurological Sciences, “La Sapienza” University, Rome, Italy

*Centro Parkinson, Istituti Clinici di Perfezionamento, 20126 Milan, Italy

Publication History

  1. Issue published online: 22 AUG 2006
  2. Article first published online: 2 MAY 2006
  3. Manuscript Accepted: 12 DEC 2005
  4. Manuscript Revised: 22 NOV 2005
  5. Manuscript Received: 29 OCT 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (58K)

Keywords:

  • [123I]ioflupane SPECT;
  • LRRK2;
  • PARK8;
  • Gly2019Ser mutation

Abstract

We measured striatal dopamine transporter binding using [123I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2-PD) and in gene-negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2-PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 ± 14 years, disease duration 9 ± 3 years, and UPDRS III motor score 21.60 ± 6.65. The control IPD group consisted of 15 patients with mean age 59 ± 9 years, disease duration 9 ± 5 years, and UPDRS III motor score 23.80 ± 8.69. [123I]ioflupane–specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2-PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between-group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD. © 2006 Movement Disorder Society

View Full Article (HTML) Get PDF (58K)